These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 32212216

  • 1. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 2. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J, Gu D, Lu H, Liu S, Kong J.
    J Thorac Oncol; 2019 Dec; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract] [Full Text] [Related]

  • 3. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
    Tao H, Liu Z, Mu J, Gai F, Huang Z, Shi L.
    Diagn Pathol; 2022 Feb 10; 17(1):27. PubMed ID: 35144623
    [Abstract] [Full Text] [Related]

  • 4. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.
    Lung Cancer; 2019 Nov 10; 137():19-22. PubMed ID: 31521978
    [Abstract] [Full Text] [Related]

  • 5. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF, Wang WX, Xu CW, Huang LC, Li XF, Lan G, Zhai ZQ, Zhu YC, Du KQ, Lei L, Fang MY.
    Lung Cancer; 2020 Apr 10; 142():59-62. PubMed ID: 32114282
    [Abstract] [Full Text] [Related]

  • 6. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ, Dai XY, Qiu Y, Liu XN, Zeng CM, Xu XY, Chen YD, Zhu H, He QJ, Gai RH, Ma SL, Chen XQ, Yang B.
    Acta Pharmacol Sin; 2024 Jun 10; 45(6):1252-1263. PubMed ID: 38360931
    [Abstract] [Full Text] [Related]

  • 7. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M, Wang K, Zhu J, Lu Y, Huang M.
    Lung Cancer; 2021 Feb 10; 152():104-108. PubMed ID: 33444901
    [Abstract] [Full Text] [Related]

  • 8. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
    Guo J, Shi J, Yao M, Jin Y, Liu D, Liu W, Wang K, Jiang D.
    Medicine (Baltimore); 2020 Nov 06; 99(45):e22631. PubMed ID: 33157918
    [Abstract] [Full Text] [Related]

  • 9. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C, Barua S, Hsiao SJ, Mansukhani M, Saqi A, Murty V, Fernandes H.
    Cold Spring Harb Mol Case Stud; 2019 Jun 06; 5(3):. PubMed ID: 31160357
    [Abstract] [Full Text] [Related]

  • 10. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H, Liu Y, Wang W, Tang Y, Tian P, Li W.
    Ann Palliat Med; 2021 Jul 06; 10(7):8352-8357. PubMed ID: 33832282
    [Abstract] [Full Text] [Related]

  • 11. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
    Tian P, Liu Y, Zeng H, Tang Y, Lizaso A, Ye J, Shao L, Li Y.
    J Cancer Res Clin Oncol; 2020 Apr 06; 146(4):935-944. PubMed ID: 31894386
    [Abstract] [Full Text] [Related]

  • 12. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 13. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N.
    Target Oncol; 2019 Apr 07; 14(2):159-168. PubMed ID: 30895431
    [Abstract] [Full Text] [Related]

  • 14. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y, Zhang X, Jiang Q, Wang B, Wang Y, Junrong Y.
    Lung Cancer; 2020 Aug 07; 146():370-372. PubMed ID: 32527613
    [Abstract] [Full Text] [Related]

  • 15. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.
    Pan X, Zhong A, Xing Y, Li X, Du H, Shi M.
    J Int Med Res; 2021 Sep 07; 49(9):3000605211044652. PubMed ID: 34590916
    [Abstract] [Full Text] [Related]

  • 16. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y.
    Thorac Cancer; 2022 Apr 07; 13(7):1088-1090. PubMed ID: 35212154
    [Abstract] [Full Text] [Related]

  • 17. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 18. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.
    J Thorac Oncol; 2019 Jul 08; 14(7):1233-1243. PubMed ID: 30902613
    [Abstract] [Full Text] [Related]

  • 19. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Zheng J, Zhu Y, Sun K, Shen Q, Wang Y, Cao H, Lizaso A, Yu B, Lin J, Chen S, Zhou J, Zhou J.
    Lung Cancer; 2020 Aug 08; 146():209-216. PubMed ID: 32563740
    [Abstract] [Full Text] [Related]

  • 20. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H, Yasugi M, Takigawa N, Hotta K, Ichihara E, Taniguchi A, Toyooka S, Hashida S, Sendo T, Tanimoto M, Kiura K.
    Jpn J Clin Oncol; 2014 Oct 08; 44(10):963-8. PubMed ID: 25170107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.